Dynavax Technologies Corp (FRA:DYF1)
€ 10.11 0.05 (0.5%) Market Cap: 1.37 Bil Enterprise Value: 937.06 Mil PE Ratio: 189.83 PB Ratio: 2.41 GF Score: 74/100

Dynavax Technologies Corp at Guggenheim Vaccine and Infectious Disease Conference (Virtual) Transcript

Oct 05, 2021 / 04:00PM GMT
Release Date Price: €15.2 (+7.95%)
Evan Wang
Guggenheim Securities LLC - Analyst

All right. Good afternoon, everyone, and thanks for joining us for today's fireside chat with Dynavax. I'm Evan Wang, a member of the Guggenheim biopharma team. I'm joined by Dynavax's Ryan Spencer, CEO; and Kelly MacDonald, CFO. Let me turn it over to Ryan quickly to start with a brief overview of Dynavax's pipeline, and then we'll jump into Q&A.

Ryan Spencer
Dynavax Technologies Corporation - CEO

Great. Thanks, Evan. I'm going to share some slides here just to help facilitate the overview. So bear with me one second while I get this set up. Okay, thank you. So first, let's just start with a brief mention of our forward-looking statements. And we encourage you to review these as well as the risk factors on our most recent SEC filings.

So a quick overview for Dynavax. I think what you really need to understand right now is the Company is being built around two highly valuable assets, the first being HEPLISAV-B, which is our adult hepatitis B vaccine. And that vaccine is adjuvanted with CpG 1018,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot